Structure Therapeutics Inc.
GPCR
Rank in Stocks
#7456
Structure Therapeutics Inc., an international biopharmaceutical company... Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Share Price
$17.36
Last synced: 2026-11-18
Market Cap
$1.26B
Change (1 day)
-4.46%
Change (1 year)
-49.42%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Structure Therapeutics Inc. (GPCR)
Category
Healthcare
EPS for Structure Therapeutics Inc. (GPCR)
EPS as of September 2026 TTM: $-3.90
According to Structure Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-3.90. At the end of 2025 the company had an EPS of $-2.40, a decrease compared to its 2024 EPS of $-2.34.
EPS history for Structure Therapeutics Inc. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.90 | 62.50% |
| 2025 | $-2.40 | 2.56% |
| 2024 | $-2.34 | -3.70% |
| 2023 | $-2.43 | 68.75% |
| 2022 | $-1.44 | 20.00% |
| 2021 | $-1.20 | 166.67% |
| 2020 | $-0.45 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -501.54% |
US
|
|
| $-7.08 | 81.54% |
US
|
|
| $-5.29 | 35.64% |
AU
|
|
| $21.56 | -652.82% |
NL
|
|
| $12.73 | -426.47% |
BE
|
Questions about Structure Therapeutics Inc.'s earnings per share (EPS)
What is Structure Therapeutics Inc.'s earnings per share (EPS)?
Structure Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-3.90, as of Sep 2026.
What was Structure Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, Structure Therapeutics Inc.'s earnings per share (EPS) was $-2.40, compared with $-2.34 in 2024.
How has Structure Therapeutics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Structure Therapeutics Inc.'s earnings per share (EPS) was highest in 2020 ($-0.45) and lowest in 2023 ($-2.43).
How does Structure Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
Structure Therapeutics Inc.'s earnings per share (EPS) ($-3.90) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.